Similar articles

• Specific keynote: clinical trial design problems in ovarian cancer.

  Stevenson A, Gore M. Stevenson A, et al. Gynecol Oncol. 2003 Jan;88(1 Pt 2):S117-21; discussion S122-3. doi: 10.1006/gyno.2002.6698. Gynecol Oncol. 2003. PMID: 12586100 Review. No abstract available.
• Seamlessly expanding a randomized phase II trial to phase III.

  Inoue LY, Thall PF, Berry DA. Inoue LY, et al. Biometrics. 2002 Dec;58(4):823-31. doi: 10.1111/j.0006-341x.2002.00823.x. Biometrics. 2002. PMID: 12495136
• New designs for the selection of treatments to be tested in randomized clinical trials.

  Simon R, Thall PF, Ellenberg SS. Simon R, et al. Stat Med. 1994 Mar 15-Apr 15;13(5-7):417-29. doi: 10.1002/sim.4780130506. Stat Med. 1994. PMID: 8023026 Review.
• Design issues in randomized phase II/III trials.

  Korn EL, Freidlin B, Abrams JS, Halabi S. Korn EL, et al. J Clin Oncol. 2012 Feb 20;30(6):667-71. doi: 10.1200/JCO.2011.38.5732. Epub 2012 Jan 23. J Clin Oncol. 2012. PMID: 22271475 Free PMC article.
• Is Bayesian analysis ready for use in phase III randomized clinical trials? Beware the sound of the sirens.

  Howard G, Coffey CS, Cutter GR. Howard G, et al. Stroke. 2005 Jul;36(7):1622-3. doi: 10.1161/01.STR.0000170638.55491.bb. Epub 2005 Jun 9. Stroke. 2005. PMID: 15947275 No abstract available.